Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

G-Pen

Other · developed by Xeris Pharmaceuticals

Phase 2 Most advanced trial (none active)
XERS Developer
1 Registered trials

What is G-Pen?

G-Pen is an investigational drug studied in Hypoglycemia.

At a glance

Drug type
Other
Therapy area
Metabolic
Developer
Xeris Pharmaceuticals (XERS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01972152 Phase 2 Hypoglycemia Completed XERS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hypoglycemia

More from Xeris Pharmaceuticals

PRAM9 Phase 2 Regular Insulin Phase 2

Follow XERS, the company behind G-Pen

See XERS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XERS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.